NCT01779206 2025-04-08
ADAPT
West German Study Group
Phase 2/3 Completed
Clinical Trials
99 trialsNCT03356860 2024-11-20
B-IMMUNE
Grand Hôpital de Charleroi
Phase 1/2 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT06309732 2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2 Completed
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
NCT02287129 2023-11-28
MEMORI
Technical University of Munich
Phase 2 Completed
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00129922 2023-03-06
Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02549677 2022-10-27
ELEGANT
Ruijin Hospital
Phase 4 Completed
NCT02050919 2022-03-21
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02400567 2022-03-15
NeoPAL
UNICANCER
Phase 2 Completed
NCT00193206 2021-11-23
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193050 2021-10-26
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02395640 2021-10-26
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Phase 3 Completed
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02742051 2021-09-23
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03289819 2021-04-08
NIB
Institut fuer Frauengesundheit
Phase 2 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00003606 2021-02-21
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
UNICANCER
Phase 3 Completed
NCT02324088 2021-02-21
PEGASE07
UNICANCER
Phase 3 Completed
NCT02685059 2021-02-15
GeparNuevo
GBG Forschungs GmbH
Phase 2 Completed
NCT01690702 2021-02-02
GAIN-2
GBG Forschungs GmbH
Phase 3 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT04659551 2020-12-09
GIADA
Istituto Oncologico Veneto IRCCS
Phase 2 Completed
NCT01026116 2020-05-12
A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old
Fudan University
Phase 3 Completed
NCT00052910 2020-05-07
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01855828 2020-03-31
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Yale University
Phase 2 Completed
NCT02789332 2020-03-17
GeparOla
GBG Forschungs GmbH
Phase 2 Completed
NCT04127019 2020-02-26
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
Fudan University
Phase 3 Completed
NCT04224922 2020-01-18
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
AZ-VUB
Phase 2 Completed
NCT02628613 2019-11-01
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
Fudan University
Phase 2 Completed
NCT02115204 2019-10-03
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
West German Study Group
Phase 3 Completed
NCT01049425 2019-08-14
planB
West German Study Group
Phase 3 Completed
NCT01216644 2019-06-19
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
Phase 2/3 Completed
NCT02042690 2019-05-29
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Peking University
Phase 3 Completed
NCT00776724 2019-05-06
TaiNAC
National Taiwan University Hospital
Phase 3 Completed
NCT01386346 2018-12-12
VEOX
Weill Medical College of Cornell University
Phase 1 Completed
NCT00822848 2018-09-07
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT00689156 2018-04-05
READ
Danish Breast Cancer Cooperative Group
Phase 3 Completed
NCT02214602 2018-03-22
NMIBCIVT
Mansoura University
Phase 4 Completed
NCT01234324 2018-01-23
NEOPECX
AIO-Studien-gGmbH
Phase 2 Completed
NCT02980965 2017-11-13
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
Fudan University
Phase 3 Completed
NCT02001506 2017-08-29
Neo-shorter
Asan Medical Center
Phase 3 Completed
NCT02125344 2017-07-13
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
GBG Forschungs GmbH
Phase 3 Completed
NCT00878904 2017-03-24
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT02365805 2017-03-13
BERNAQ
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 2 Completed